Anders Blanck joins the Board of Addeira Pharmaceuticals AB

Anders Blanck is a well-known profile in the healthcare sector and has been active in leading roles in the industry for many years. He has, among other things, been CEO of the Pharmaceutical Industry Association (LIF), where he successfully worked to strengthen the dialog between the pharmaceutical industry, politicians and healthcare. His broad knowledge and strategic thinking will be a great asset to Addeira Pharmaceuticals.

"We are very pleased to welcome Anders Blanck to our Board of Directors," said Anders Torell, Chairman of Addeira Pharmaceuticals AB. "His solid experience and understanding of both the Swedish and international pharmaceutical markets will be invaluable in our quest to commercialize effective treatment solutions for patients."

Anders Blanck is looking forward to his new role and to contributing to Addeira's vision: "I am very impressed by Addeira Pharmaceuticals and their ambition to deliver innovative products to both pharmacies and healthcare. I look forward to contributing to the board work to develop the company further."

Addeira Pharmaceuticals AB focuses on [brief description of the company's business and objectives]. With Anders Blanck on the Board, the company strengthens its position and continues to build a solid foundation for future development of a pharmaceutical portfolio. The Board of Directors consists of Anders Blanck, Anders Torell (Chairman) and the founders Robert Svanström and Malkolm Makdessi Elias.